COTA Genomic Profiling Study Released
12.11.19
A retrospective review of the COTA Real World Data (RWD) database was performed to identify patients with pathologically confirmed metastatic colon cancer (mCC) diagnosed between January 1, 2013 and December 1, 2017. Although guidelines recommend molecular testing for patients with mCRC, the current study included patients with mCC and excluded rectal cancer cases. At the time of data extraction, the COTA database included demographic, diagnostic, treatment, and quality-of-care information for patients with colon cancer abstracted from the electronic health records from 23 practices including 258 oncologists in Arkansas, Maryland, Michigan, New Jersey, New York, and Tennessee who contribute data under Business Associate Agreements. All data were de-identified to be compliant with Health Insurance Portability and Accountability Act and Office of Health Promotion Research regulations for purposes of secondary research use. The structure of the COTA database has been reviewed by the Western Institutional Review Board and has been deemed exempt from patient informed consent. Read Full Release
Boston Millennia Partners
COTA Welcomes Daniel Lane as Vice President for HEOR to Drive Outcomes-Based Research in Oncology
07.25.19
COTA, Inc., a leading precision medicine technology company that uses real-world data to bring clarity to cancer care, has named Daniel Lane as its new Vice President for Health Economics and Outcomes Research (HEOR). Daniel brings extensive experience in leading oncology outcomes research organizations, and leveraging innovative datasets to generate impactful real world evidence (RWE) across multiple healthcare sectors. Combining this with COTA’s expertise and understanding of real-world data will allow the company to better support its partners as they improve access and quality in healthcare. Read Full Release
COTA
COTA, Inc. Announces Headquarter Relocation to Boston for Continued Growth
08.01.19
COTA, Inc., a healthcare technology company that uses real-world evidence to bring clarity to cancer care, has announced that the Company’s headquarters will be relocating to Boston on August 1, 2019. The Company will maintain a New York City presence, but will continue to grow and reinforce its operational activities in Boston. Boston’s robust health technology and life science industries fit perfectly with COTA’s mission of improving cancer care. The Company will be located at 101 Arch Street Read Full Release
FDA Leverages Private Sector Technology-Based Tools In Its Embrace Of Real World Evidence
07.09.19
The agency has signaled its apparent change of heart with speeches, policy guidance, and now with two public-private partnerships: the recent expansion of its agreement with Flatiron Health, and a brand new collaboration with COTA Healthcare. The Flatiron collaboration initially focused on patients being treated with immunotherapy for advanced non-small cell lung cancer; the new work concerns “the use of RWE in regulatory decision-making, including characterization of data quality, validation of reliable real-world clinical endpoints, collaboration on new analytic methodologies, and exploration of innovative applications such as real-world control arms.” The COTA collaboration will focus on breast cancer patients and treatment options. Read Full Release
Boston Millennia Partners
Dana Callow to speak at Opal’s Family Office & Private Wealth Management Forum in Newport 7.23.19
07.10.19
As Opal Financial Group’s flagship event, The Family Office & Private Wealth Management Forum has become Opal’s largest family office event in the world. Known for its rich history and magnificent mansions, Newport, RI attracts thousands of delegates each year. The voyage begins with an annual Regatta Cup race, giving delegates an opportunity to find their inner competitor, and race across the harbor. In the course of three days, family offices, private investors, and investment managers navigate their way through the choppy waters of the past recession, while continuing to explore the best ways to map out their portfolios. With over 1000 delegates there is always an opportunity to meet potential clients. Discussions will cover a wide variety of investment topics including direct investing, impact investing, non-correlated assets, and many more. Come join us this July-- the forecast calls for fun, networking, and favorable prospects for preserving your family’s wealth. Read Full Release
COTA Signs Research Collaboration Agreement With The U.S. Food and Drug Administration
05.29.19
COTA, Inc., a leading precision medicine technology company that uses real-world evidence to bring clarity to cancer care, today announced it has signed a two-year Research Collaboration Agreement (RCA) with the U.S. Food and Drug Administration (FDA) Information Exchange and Data Transformation (INFORMED) Program, the Agency's data science and technology incubator supporting regulatory science research. This RCA will establish a study protocol with an initial focus on breast cancer, and will provide the FDA with information on the evolving treatment landscape, including insight on treatment variation within defined subpopulations of patients with the disease. As the project advances, the research may expand to other cancer types and explore disease characteristics, treatment patterns, and patient outcomes for the broader application of precision medicine. Read Full Release
COTA to attend ASCO May 31st – June 4th, 2019
05.31.19
Attending #ASCO19 5/31-6/4? Stop by Booth #2063 to learn how COTA organizes fragmented, often hidden data from the real world to provide a clear view of cancer or schedule a demo with us here: meetus@cotahealthcare.comFind more details about the attending here. Read Full Release
Forefront Telecare, Behavioral Health Solution for Rural Americans, Completes $15 Million Growth Equity Funding Round
04.24.19
Boston, MA, April 2019 Boston Millennia Partners IV is pleased to announce its investment in Forefront Telecare, Inc. as part of a $15 million growth equity round. Forefront is a leading provider of behavioral services via Telehealth to vulnerable populations across the country. With a focus on high acuity psychiatric patients in rural markets, Forefront offers services to hospitals, skilled nursing facilities, and clinics that have limited access to behavioral health practitioners. The solution consists of an extensive provider network, a modern video conferencing platform, and scalable in-house billing. The company currently serves over 175 customers and will be relocating headquarters to New Jersey. Read Full Release
Health Decisions Appoints Sheila Kiss as Head of European Clinical Operations
03.31.19
Health Decisions, Inc., the full-service clinical research organization (CRO) of choice for forward-looking biopharma and medical device companies and a leader in women’s health and diagnostics studies, has appointed Sheila Kiss as Head of European Clinical Operations. With more than 35 years’ experience in Clinical Operations and Project Management, Kiss will support Health Decisions’ dedicated Clinical Operations Team to execute research in Women’s Health and In Vitro Diagnostic clinical development. Read Full Release
MEDAPTUS NAMES DR. SUSAN KATZ SLISKI AS CHIEF NURSING OFFICER
02.05.19
Susan Katz Sliski, DNP, RN, CCM, FAAOHN has been named the Chief Nursing Officer (CNO) for MedAptus, Inc. In her role, Dr. Katz Sliski will be working closely with the product management team to promote and improve all MedAptus products, with a special focus on ASSIGN for Nurses, the company’s flagship patient assignment software for nurses. In her most recent role prior to joining MedAptus, Dr. Katz Sliski was leading REDESIGN initiatives within healthcare organizations to improve patient and provider experiences, drive organizational effectiveness and decrease costs. Read Full Release
MedAptus
MEDAPTUS RANKED #1 IN KLAS RANKINGS FOR MOBILE CHARGE CAPTURE IN 2019
01.31.19
“This is one more indication of our commitment towards providing the very best charge management solutions in healthcare,” said Eugene Schneider, MedAptus president and CEO. “Whether it’s for professionals, facilities or even infusion coding services, our charge capture, management and reconciliation processes are consistently finding new sources of revenue for our customers. That’s extremely important as hospitals and other entities continue to tighten belts in this very challenging healthcare environment.” Read Full Release
COTA
HIMSS19: The Importance of Data and Managing Expectations
02.01.19
It’s that time of year again! As we get ready for all that HIMSS has to offer and learn about exciting opportunities in healthcare, it’s important to manage expectations around what is going to be accomplished at the conference. It’s no surprise that HIMSS continues to get bigger and bigger every year, but many of the same things are still being discussed - Artificial Intelligence (AI), Machine Learning, Natural Language Processing, data security and improving efficiencies, to name a few. Read Full Release
To Improve Treatments, Researchers Want To Hunt For Clues In Medical Records
07.15.18
When you go to your doctor's office, sometimes it seems the caregivers spend more time gathering data about you than treating you as a patient. Electronic medical records are everywhere – annoying to doctors and intrusive to patients. But now researchers are looking to see if they can plow through the vast amount of data that's gathered in those records, along with insurance billing information, to tease out the bits that could be useful in refining treatments and identifying new uses for drugs. Read Full Release
COTA
Data sharing company helps improve cancer patient outcomes, reduce total cost of care
07.13.18
Over the years oncologists and health care experts have struggled to find new ways to reduce the cost of cancer treatment. The American Cancer Society estimates patients paid nearly $4 billion in out-of-pocket costs in 2014, and that the disease cost the country around $88 billion in cancer-related health care spending that same year. Some doctors are now looking at emerging oncology data companies to help reduce that financial burden all while improving clinical outcomes. Read Full Release
Health Decisions
US CRO Health Decisions and European CRO/SMO Comac Medical Expand Transatlantic Collaboration in Women’s Health
06.27.18
Durham, North Carolina and Sofia, Bulgaria. Health Decisions, Inc., the leading US full-service women’s health specialty CRO and Comac Medical, a full-service CRO/SMO operating in 24 European countries, today announced an expansion of their strategic alliance to conduct women’s health clinical trials in the United States, Western and Central and Eastern Europe. “Health Decisions is pleased to strengthen its strategic women’s health alliance with our colleagues at Comac Medical,” stated Health Decisions’ Chief Executive Officer Patrick Phillips, BSc (Hons), D.Phil. “The Health Decisions/Comac Medical alliance provides sponsors of women’s health trials with extensive therapeutic and operational expertise and access to hundreds of investigational women’s health sites in the United States and Europe. These regions provide care for hundreds of millions of women and generate approximately two-thirds of the revenues of the global biopharmaceutical industry. This strategic alliance will enable Health Decisions to fulfill its mission of improving healthcare outcomes for women worldwide and assisting sponsors who share that goal.” Read Full Release
COTA
Cota Founder and Executive Chairman to Present at the Vatican’s Unite to Cure Conference
04.27.18
Cota Inc., a real-world data and analytics company bridging precision medicine to population health, today announced its founder and executive chairman, Andrew Pecora, M.D., will speak today, April 27 at the Fourth International Vatican Conference, Unite to Cure: A Global Health Care Initiative, which is being held from April 26-28 at the Aula Nuova del Sinodo in Vatican City. The event will build on the current global health care movement and unite world leaders across all disciplines to engage in powerful conversations about how science, technology and 21st century medicine will impact culture and society. Read Full Release
COTA
HIMSS18: Interview with Stuart Goldberg, M.D. | Cota | Precision Payment
03.29.18
On this episode we talk with Stuart Goldberg, MD, Chief Scientific Officer at Cota. Dr. Goldberg tells us all about Cota’s physician-led journey to organize and classify real-world evidence about every type of cancer. This effort led to something they call the Cota Nodal Address (CNA), and it’s enabling health systems to get very specific about the types of patients they’re treating, the costs associated with them, and the outcomes being achieved. This apples-to-apples comparison allows Cota to identify variation and address it in ways that are beneficial to the provider, payer and patient. It enables a concept Dr. Goldberg calls “Precision Payment”, which in turn enables proper bundled payment design, and precision medicine. Read Full Release
COTA
Beyond Flatiron: The Rising Power Of Oncology Clinical Data Companies
03.10.18
First, given that (as Andrew Matzkin of Health Advances observed) the Flatiron transaction is “putting smiles on a lot of faces,” what other emerging oncology clinical data companies might soon be in play? And second, more fundamentally, what are the implications of the rise of these types of companies – for both pharma and for healthcare? Read Full Release
COTA
Cota Announces $40 Million Series C Financing to Advance its Cota Nodal Address™ Classification System and Real-World Evidence and Analytics Platforms
02.21.18
Cota Inc., a healthcare real-world evidence and data analytics company bridging precision medicine to population health, today announced the completion of a Series C round of financing led by IQVIA (NYSE: IQV) with major participation by EW Healthcare Partners. Cota will leverage this funding to scale its solutions across healthcare providers, payers and life sciences companies. The funding will also advance its proprietary Cota Nodal Address™ (CNA) system, a powerful and unique precision disease classification system built on its comprehensive real-world data set. Memorial Sloan Kettering Cancer Center also participated in the round, along with existing Cota investors which include, Boston Millennia Partners, Horizon Blue Cross Blue Shield of New Jersey, Hackensack Meridian Health and Atoc Holdings. Read Full Release
MedAptus
MedAptus Named 2018 Top-Ranked Mobile Charge Capture Platfrom by KLAS Research
02.01.18
For the seventh time in eight years, MedAptus® has been named the Category Leader in the Mobile Charge Capture segment in the “2018 Best in KLAS Awards: Software & Services” report. The award recognizes the performance of its CHARGE PRO software product, a charge capture, management and reconciliation that improves financial performance for physicians and hospitals by accurately converting billable services into ICD-10 codes quickly and easily. The company’s top-ranking score of 91.9 reflects feedback from customers across measures evaluating vendor performance data and overall satisfaction. Read Full Release